Clinical Isolate Core (Core B)

项目摘要/摘要 临床分离核心(核心B)的总体目标是提供对强大的临床 细菌分离株和评价抗生素的标准化和实验控制平台 异质电阻(HR)跨学科研究单位(HR-IRU)。因此，核心B是 对HR-IRU计划的全面成功至关重要。为了实现核心目标，我们组建了一个 多学科团队包括一名传染病临床医生(雅各布)，一名研究科学家(萨托拉)，一个董事会- 注册医学微生物学家(BURD)和流行病学家(图纳利)，具有广泛的抗生素专业知识 抵抗。对于核心B，使研究项目能够成功完成，并促进我们的理解 对于抗生素HR，我们提出了三个具体目标。1)提供临床细菌分离的途径。分离物 (肠杆菌和鲍曼不动杆菌复合体)将作为疾病中心的一部分收集 控制和预防(CDC)佐治亚州新发感染计划(EIP)多点革兰氏阴性 监测倡议(MuGSI)，埃默里大学的临床微生物学研究核心(ICMC) 瑞典乌普萨拉大学医院。2)对临床分离的细菌进行HR分析。我们会 每年从血液、尿液和呼吸道临床感染中检测500株细菌：200种多种药物 来自佐治亚州EIP的耐药微生物(MDRO)；来自ICMC的100个非MDRO和200个主要 来自瑞典乌普萨拉大学医院的敏感菌株。将对每个分离株进行HR测试，以 大约20种抗生素使用人口分析概况(PAP)，这是人力资源的黄金标准。3)执行 流行病学分析揭示了HR的患病率、类型和趋势。我们将确定疾病的流行率 在AIM 2中测试的2500个分离株中的HR。我们将对 有HR的分离株的临床和实验室特征，并与无HR的分离株进行比较。核心B将 在佐治亚州EIP和埃默里大学的ICMC的实验室进行，这两个实验室拥有广泛的 在以活跃人口为基础的人力资源监测和研究方面的专业知识。核心领导层将与 HR-IRU项目总监/绩效指标和项目负责人确保严格满足所有项目的需求 以可靠、可重现和及时的方式。

PROJECT SUMMARY/ABSTRACT The overall objective of the Clinical Isolate Core (Core B) is to provide access to a robust collection of clinical bacterial isolates and a standardized and experimentally controlled platform for evaluating antibiotic heteroresistance (HR) for the Heteroresistance Interdisciplinary Research Unit (HR-IRU). Core B is therefore essential to the overall success of the HR-IRU program. To accomplish Core goals, we have assembled a multidisciplinary team including an infectious disease clinician (Jacob), a research scientist (Satola), a board- certified medical microbiologist (Burd) and an epidemiologist (Tunali) with expertise vast areas of antibiotic resistance. For Core B to enable successful completion of the research projects and advance our understanding of antibiotic HR we propose three specific aims. 1) To provide access to clinical bacterial isolate. Isolates (Enterobacterales and Acinetobacter baumanii complex) will be collected as part of the Centers for Disease Control and Prevention's (CDC) Georgia Emerging Infections Program (EIP) Multi-site Gram-negative Surveillance Initiative (MuGSI), Emory University's Investigational Clinical Microbiology Core (ICMC) biorepository, and Uppsala University Hospital, Sweden. 2) To profile clinical bacterial isolates for HR. We will test 500 bacterial isolates per year from bloodstream, urine, and respiratory clinical infections: 200 multi-drug resistant organisms (MDRO) from the Georgia EIP; 100 non-MDRO from the ICMC and 200 predominately susceptible isolates from Uppsala University Hospital, Sweden. Each isolate will be tested for HR to approximately 20 antibiotics using population analysis profiling (PAP), the gold standard for HR. 3) To perform epidemiological analyses revealing the prevalence, type and trends of HR. We will establish the prevalence of HR from the 2500 isolates tested in aim 2. We will perform comprehensive descriptive epidemiology on the clinical and laboratory characteristics of isolates with HR and compare those to isolates without HR. Core B will be conducted in the laboratories of the Georgia EIP and Emory University's ICMC, which have extensive expertise in active-population based surveillance and studies of HR. The Core leadership will work closely with the HR-IRU program directors/PIs and project leaders to ensure that the needs of all projects are rigorously met in a reliable, reproducible and timely manner.